-
Benzyl-activated Streptavidin Magnetic Beads
2026-09-05
Benzyl-activated Streptavidin Magnetic Beads (SKU: K1301) provide magnet-assisted capture of biotinylated proteins, nucleic acids, peptides, antibodies, and other targets from complex samples. They are suitable for affinity purification, immunoprecipitation, interaction assays, and screening, but preservative compatibility, elution conditions, and performance with non-biotinylated or highly hydrophobic samples require validation.
-
Zolmitriptan Workflow for 5-HT1B Research
2026-09-04
Build reproducible serotonin receptor assays with Zolmitriptan, a research compound suited to migraine and cluster headache models. This guide combines solvent control, time-resolved pharmacology, subtype validation, and lysosome-study-inspired experimental design without overstating cross-domain evidence.
-
Small Molecules Improve Pancreatic Ductal Organoids
2026-09-04
Liao and colleagues developed a small-molecule-based culture strategy for generating pancreatic ductal organoids with improved initiation efficiency, ductal-cell enrichment, and long-term expansion. The model retains heterogeneous ductal and acinar populations, making it useful for studying exocrine biology, cellular plasticity, pancreatic disease, and future drug-screening workflows.
-
Mubritinib (TAK 165): Reading Complex I Assays
2026-09-03
Mubritinib (TAK 165) is best interpreted through mitochondrial redox biology rather than a HER2-only framework. This article connects complex I inhibition with NAD+/NADH homeostasis to improve assay design in AML, PEL, and related cancer biology studies.
-
BET Inhibition in HPV-16 HNSCC: Study Insights
2026-09-03
This preprint examines how BET protein inhibition affects viral and cellular transcription in HPV-16-associated head and neck squamous cell carcinoma. Its central contribution is showing that responses are heterogeneous across models, while convergent effects on BRD4, c-Myc, E2F, CDKN1A, and cell-cycle control provide a framework for interpreting BET-targeted experiments.
-
Podophyllotoxin Beyond the Product Page
2026-09-02
A mechanism-first guide to using Podophyllotoxin as a microtubule benchmark in cancer biology, while interpreting autophagy and hepatocellular carcinoma findings from the distinct natural product JXE-23.
-
Flubendazole: Autophagy Research Guide
2026-09-02
Flubendazole is a benzimidazole-derived autophagy activator supplied for research use. This guide distinguishes its documented product properties from breast-cancer pathway evidence involving tumor-associated macrophage extracellular vesicles, miR-660, KLHL21, and NF-κB signaling.
-
TSPAN18–STIM1 Signaling in Prostate Cancer Bone Metastasis
2026-09-01
Zhou et al. identify TSPAN18 as a regulator of STIM1 stability and show that it promotes prostate cancer bone metastasis by preventing TRIM32-mediated ubiquitination of STIM1. The study connects a protein-stabilization mechanism with STIM1-dependent calcium influx, cancer-cell motility, and clinically adverse metastatic features, providing a mechanistic framework for studying this signaling axis.
-
Antipyrine in BBB Permeability Research
2026-09-01
Antipyrine provides a highly soluble, high-purity reference compound for connecting pain and fever pharmacology with reproducible barrier-transport workflows. Used alongside LLC-PK1-MOCK/MDR1 assays, it helps researchers separate passive permeability, efflux, recovery loss, and handling artifacts before committing to costly in vivo studies.
-
Flubendazole for Autophagy Research Workflows
2026-08-31
Flubendazole enables controlled autophagy perturbation in cancer, neurodegeneration, and metabolism-linked cell models. This practical guide connects DMSO-based handling and flux-aware readouts with the hepatic stellate cell glutamine-metabolism findings reported in a liver fibrosis study.
-
WQ-C-401 and PDGFR Control of PAH Remodeling
2026-08-31
The reference study identifies WQ-C-401 as a selective PDGFR inhibitor that reduces pulmonary vascular remodeling and right-heart stress in monocrotaline-induced pulmonary arterial hypertension. Its combined kinome, cell, biochemical, and animal evidence provides a useful framework for evaluating PDGFR-driven disease biology while highlighting the limitations of translating kinase inhibition across models.
-
Azithromycin and Roxithromycin as Senolytics
2026-08-30
Ozsvari and colleagues used a DNA-damage-induced human fibroblast model to identify azithromycin and roxithromycin as clinically approved antibiotics with selective senolytic activity. Their study combines viability, real-time impedance, and metabolic analyses, providing a practical drug-repurposing framework while also showing why senescent cell detection should use complementary readouts.
-
Angiotensin I/II (1-5) RAS Workflow Guide
2026-08-29
Angiotensin I/II (1-5) provides a defined Asp-Arg-Val-Tyr-Ile peptide fragment for controlled renin-angiotensin system research, including blood pressure, renal, and aldosterone-related assays. It is not a general-purpose angiotensin substitute and should not be applied to unrelated signaling workflows without independent validation of identity, solubility, and assay response.
-
Azithromycin and Roxithromycin as Senolytics
2026-08-28
The 2018 study identified azithromycin and roxithromycin as clinically approved macrolide antibiotics that preferentially eliminate DNA-damage-induced senescent human fibroblasts. Its combination of selective viability screening, metabolic analysis, and real-time impedance validation provides a useful framework for studying senolytic drug repurposing while highlighting the limitations of extrapolating cell-culture findings to other antibiotic applications.
-
RIPA Lysis Buffer Strong for PDAC Protein Workflows
2026-08-28
RIPA Lysis Buffer Strong delivers powerful membrane disruption for protein extraction from pancreatic cancer cells, tissues, and macrophage models. Its inhibitor-free format lets researchers customize protection strategies for Western blotting, immunoprecipitation, ELISA, and kinase-focused workflows.